This Amendment No. 4 to the Tender Offer Statement on Schedule TO (this
Amendment) amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on October 13, 2023 (as it may be further amended and supplemented from time to time, the Schedule
TO) and relates to the offer by Yosemite Falls Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation (Lilly), to purchase all of the issued and outstanding
shares of common stock, par value $0.0001 per share (the Shares), of POINT Biopharma Global Inc., a Delaware corporation (POINT), at a purchase price of $12.50 per Share, net to the stockholder in cash, without interest and
less any applicable tax withholding, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated October 13, 2023, and in the related Letter of Transmittal (which, together with the Offer to Purchase, each as amended
or supplemented from time to time, collectively constitute the Offer), copies of which are attached to the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by
reference to the extent relevant to the items in this Amendment. Capitalized terms used but not defined herein have the respective meanings ascribed to them in the Schedule TO.
Items 1 through 9 and Item 11.
The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented as follows:
On November 17, 2023, in order for the parties to satisfy the Minimum Tender Condition, Lilly announced an extension of the
Expiration Time until 5:00 p.m., Eastern Time, on December 1, 2023, unless the Offer is further extended or earlier terminated. The Offer was previously scheduled to expire at 5:00 p.m., Eastern Time, on November 16, 2023. In case the
Offer is extended again, a public announcement of such extension will be made no later than 9:00 a.m., Eastern Time, on the business day after the previously scheduled Expiration Time. The procedures regarding the extension of the Expiration Time
are described in Section 1 Terms of the Offer of the Offer to Purchase.
The Depositary has advised Purchaser that,
as of 5:00 p.m., Eastern Time, on November 16, 2023, approximately 28,186,065 Shares have been validly tendered and not properly withdrawn pursuant to the Offer, representing approximately 26.45% of the outstanding Shares as of such date
and time.
The press release announcing the extension of the Offer is attached as Exhibit (a)(5)(D) to the Schedule TO and incorporated
herein by reference.
Amendments to the Offer to Purchase and Exhibits to the Schedule TO
The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented as follows:
All references to 5:00 p.m., Eastern Time, on November 16, 2023 set forth in the Offer to Purchase (Exhibit (a)(1)(A)), Form
of Letter of Transmittal (Exhibit (a)(1)(B)), Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (Exhibit (a)(1)(C)) and Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies
and Other Nominees (Exhibit (a)(1)(D)) shall be replaced with 5:00 p.m., Eastern Time, on December 1, 2023.
Item 12.
Exhibits.
Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit: